# Diabetes Research Hub — Monitor Review
**Run date:** 2026-06-30 (automated)
**Prior review:** monitor_report_2026-06-29.md
**Scope:** Read-only review of latest script outputs + web check. No files modified.

---

## Bottom Line (what's actionable)

1. **One status change worth a tracker entry:** Sanofi's **frexalimab** T1D beta-cell-preservation trial (NCT06111586, Phase 2) flipped **RECRUITING → ACTIVE_NOT_RECRUITING** — enrollment is closed, so results are now on a clock. This is the only material trial change today.
2. **Two new trials, both low-priority** (acupuncture for sleep in elderly comorbid patients; wearable insoles for diabetic ulcer prevention). Neither is Phase 3 or from a key org. No action beyond logging.
3. **No new results posted** to ClinicalTrials.gov in the last 24h (steady at 306 trials with results).
4. **Gap analysis is fresh (today)** and continues to point at the same Tier-1-aligned white space: **Drug Repurposing** and **Health Equity** intersections dominate the top 25. This is on-doctrine — consider it a standing prompt to act, not just observe.
5. **No genuinely new breaking news in the last 7 days.** The big June items (retatrutide Phase 3, Tzield Stage 3 approval) are 3+ weeks old and already in scope.

---

## File System Status

All five key data files are present and **fresh (generated today, 2026-06-30):**

| File | Last modified | Status |
|------|--------------|--------|
| hub_monitor_report.md | 2026-06-30 07:13 | ✅ current |
| clinical_trials_latest.json | 2026-06-30 07:05 | ✅ current |
| pubmed_recent_latest.json | 2026-06-30 07:06 | ✅ current |
| literature_gap_data.json | 2026-06-30 07:13 | ✅ current |
| literature_gap_report.md | 2026-06-30 07:13 | ✅ current |

**Stale-file flag:** hub_monitor.py flags 760 result files older than 14 days. This is expected — the bulk are dated daily snapshots (`clinical_trials_snapshot_*`, `pubmed_recent_snapshot_*`) retained as history. No action needed; the *latest* pull of every data type is current.

**Secondary outputs older than 14 days** (refresh only if you plan to use them): islet drug-repurposing analysis (Apr 3), microbiome ML pipeline (Apr 4), evidence/gap network JSONs last touched Jun 29 via the iterate run. The agent_state and validation files refreshed Jun 29.

---

## Clinical Trial Changes (vs. 2026-06-29 snapshot)

**Snapshot diff:** +2 new, −1 removed, 1 status change, 0 new results. Total tracked: **839 trials.**

**Status change (flag for tracker):**

- **NCT06111586** — *Frexalimab in Preservation of Endogenous Insulin Secretion vs. Placebo* (Sanofi, Phase 2) — **RECRUITING → ACTIVE_NOT_RECRUITING.** Anti-CD40L approach to preserving beta-cell function in new-onset T1D. Closure of enrollment means a readout is the next milestone to watch.

**New trials (low priority):**

- **NCT07554235** — Auricular acupuncture for sleep quality in elderly comorbid diabetes/hypertension (Jiangsu Taizhou People's Hospital, NA, RECRUITING).
- **NCT07674420** — Wearable insoles for recurrent diabetic ulcer prevention (Johns Hopkins, NA, ACTIVE_NOT_RECRUITING).

**Removed:**

- **NCT05984238** — ReCET procedure trial (EMINENT-2). Dropped from the active query window; verify whether completed/withdrawn before assuming significance.

**Key Phase 3 trials still in flight (no change today, for context):**

- Vertex **VX-880** (zimislecel) cell therapy — NCT06832410 & NCT04786262, both Phase 3 **RECRUITING.** Vertex VX-264 (encapsulated) NCT05791201 Phase 1/2 active.
- **Teplizumab** NCT07088068 (Phase 3, RECRUITING); Japanese study NCT06791291 (Phase 2, RECRUITING).
- **Baricitinib** beta-cell preservation — NCT07222137 & NCT07222332, both Phase 3 **RECRUITING** (Eli Lilly).
- Lilly incretins — **orforglipron** and **retatrutide** programs span multiple Phase 3 (mix of active/completed/not-yet); **CagriSema** (Novo) Phase 3 program active/recruiting.

47 trials are currently Phase 3 + RECRUITING across the corpus.

---

## PubMed Highlights (30-day lookback, 162 unique papers)

**Cross-domain papers (highest value — 4 new today):**

- **[42366647]** CagriSema dual-chamber pen usability study — *T2D GLP-1 New* + key therapy **CagriSema**.
- **[42368316]** Gut microbiota in diabetic foot ulcers — *Microbiome* + *Multi-Omics*.
- **[42372727]** Microbiome–immune-cell interplay in metabolic homeostasis — *Microbiome* + *Multi-Omics*.
- **[42373794]** Probiotics as modulators of the gut-derived incretin axis (GLP-1/GLP-2) in T2D — *T2D GLP-1 New* + *Microbiome*.

The microbiome ↔ multi-omics / incretin clustering is the notable signal — it sits squarely in Tier 1 (Multi-Omics Biomarker Integration) and Tier 2 (Microbiome-Metabolic Pathway). Worth a closer read of 42372727 and 42373794 together.

**Key-therapy mentions in the corpus:** orforglipron (4 — incl. hepatic safety, head-to-head vs. dapagliflozin, insulin add-on), CagriSema (4), baricitinib (3, mostly non-diabetes RA/VEXAS — noise), teplizumab (3, incl. CGM-based early response assessment), retatrutide (2). No zimislecel publications this cycle.

**Volume trend:** ~38 papers rotated in / 38 out vs. yesterday — normal daily churn. No domain spiked or went silent.

---

## Gap Analysis Summary (generated 2026-06-30)

Top 5 under-researched intersections (all gap score 100.0, "HIGH" opportunity):

| Rank | Intersection | Joint Pubs | Expected |
|------|-------------|-----------|----------|
| 1 | Beta Cell Regen × Health Equity | 0 | 1,689 |
| 2 | Insulin Resistance × Islet Transplant | 1 | 2,212 |
| 3 | Insulin Resistance × Closed Loop/AP | 3 | 6,096 |
| 4 | Islet Transplant × GWAS/Polygenic | 0 | 1,141 |
| 5 | Islet Transplant × Personalized Nutrition | 0 | 401 |

**Tier-1 alignment:** The top-25 list is heavy with **Drug Repurposing** (ranks 6, 17, 22–25) and **Health Equity** (ranks 1, 8, 15, 18, 24) pairings — both are Tier 1 contribution areas in the Research Doctrine (Drug Repurposing Computational Screening, Epidemiological/Health Equity Analysis), and **Literature Synthesis & Gap Analysis** is itself Tier 1. Caveat per doctrine: these are relative measures; low counts may reflect terminology mismatch rather than true white space. Treat "Islet Transplant ×" gaps cautiously — the domain has only 247 total pubs, so any pairing looks empty.

---

## Breaking News (web check, last 7 days)

**Nothing genuinely new in the trailing 7-day window.** The significant June items are already 3+ weeks old and within existing scope:

- **Retatrutide** first Phase 3 results in T2D + obesity (incl. OSA and knee OA benefits) — presented at **ADA Scientific Sessions, New Orleans, June 5–8, 2026.**
- **Tzield (teplizumab)** approved for **Stage 3 T1D** in the U.S. (~June 10, 2026) — expanded indication.

Routine: a first generic dapagliflozin and oral semaglutide for weight loss are circulating in news but not new this week. No FDA diabetes action in the last 7 days.

---

## Recommended Actions

1. **Update the tracker** with the frexalimab status change (NCT06111586 → ACTIVE_NOT_RECRUITING); add a watch note for its eventual readout. This is the one item that earns a tracker edit today.
2. **Read together:** PMIDs 42372727 + 42373794 (microbiome–incretin–immune axis) — cross-domain, Tier-1-relevant; candidate for a synthesis note.
3. **Verify NCT05984238** (ReCET/EMINENT-2) removal — confirm completed vs. withdrawn so the drop isn't silently lost.
4. **No re-runs needed.** All four primary scripts (clinical trials, PubMed, gap analysis, hub monitor) ran successfully today. Next scheduled refresh is sufficient.
5. **Standing prompt (not urgent):** the gap analysis keeps surfacing Drug Repurposing × {Health Equity, CGM, Closed Loop} as open territory aligned with Tier 1. If choosing a next computational project, this is the doctrine-backed direction.

---
*Evidence note (per Research Doctrine): trial/status facts above are Level 1 (primary registry data from ClinicalTrials.gov snapshots). PubMed items are Level 2 (abstract-level, not yet full-text verified). Web/breaking-news items are Level 3 (secondary reporting). No new claims were entered into the evidence base by this review.*
